secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001104659-24-046108
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics raises $40M in private placement to fund DKN-01 clinical trials
--------------------------------------------------------------------------------

- Gross proceeds ~$40M from sale of 12.66M shares at $2.82 and pre-funded warrants for 1.52M shares at $2.819.
- Financing expected to close April 15, 2024; investors include Gilead Sciences and other institutional investors.
- Proceeds to expand DeFianCe colorectal cancer study from 130 to 180 patients and advance DisTinGuish gastric cancer study.
- Cash runway extended into Q2 2026; funds also used for Phase 3 readiness manufacturing and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/0001104659-24-046108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/tm2411534d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer